Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetic interactions between statins and fibrates.

Alberto Corsini1, Stefano Bellosta, Michael H Davidson

  • 1Department of Pharmacological Sciences, University of Milan, Milan, Italy. Alberto.corsini@unimi.it

The American Journal of Cardiology
|November 18, 2005
PubMed
Summary

Combining fibrates and statins can benefit dyslipidemia patients when statins alone are insufficient. This review examines pharmacokinetic interactions and risks of combined statin-fibrate therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

Corrigendum to "Heated tobacco product aerosol emission compared to cigarette smoke: A scoping review" [Toxicol. Rep. 16 (2026) 102209].

Toxicology reports·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Dyslipidemia management often requires combination therapy.
  • Statins effectively lower low-density lipoprotein cholesterol (LDL-C).
  • Fibrates improve high-density lipoprotein cholesterol (HDL-C) and triglyceride levels, but may not adequately address LDL-C.

Purpose of the Study:

  • To review the pharmacokinetic interactions between statins and fibrates.
  • To assess the risks and therapeutic advantages of concomitant statin-fibrate therapy.
  • To guide optimal use of combination lipid-lowering treatments.

Main Methods:

  • Literature review of pharmacokinetic studies.
  • Analysis of drug-drug interaction data for statin-fibrate combinations.

Related Experiment Videos

  • Evaluation of clinical trial data on combination therapy efficacy and safety.

    • Main Results:

    • Specific statins and fibrates exhibit varying pharmacokinetic profiles.
    • Potential for pharmacokinetic interactions exists, influencing drug exposure and efficacy.
    • Combination therapy can achieve lipid goals not met by monotherapy but requires careful monitoring.

    Conclusions:

    • Concomitant statin-fibrate therapy offers benefits for specific dyslipidemia patients.
    • Understanding pharmacokinetic interactions is crucial for safe and effective combination treatment.
    • Risk management strategies are necessary to mitigate potential adverse events from drug-drug interactions.